Who are Pemetrexed plus Carboplatin or Cisplatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pemetrexed-plus-carboplatin-or-cisplatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pemetrexed plus Carboplatin or Cisplatin — Competitive Intelligence Brief

Pemetrexed plus Carboplatin or Cisplatin (Pemetrexed plus Carboplatin or Cisplatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifolate antimetabolite combined with platinum-based chemotherapy. Area: Oncology.

phase 3 Antifolate antimetabolite combined with platinum-based chemotherapy Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Pemetrexed plus Carboplatin or Cisplatin (Pemetrexed plus Carboplatin or Cisplatin) — Avistone Biotechnology Co., Ltd.. Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while carboplatin or cisplatin are platinum-based agents that cross-link DNA, together inducing cancer cell death.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pemetrexed plus Carboplatin or Cisplatin TARGET	Pemetrexed plus Carboplatin or Cisplatin	Avistone Biotechnology Co., Ltd.	phase 3	Antifolate antimetabolite combined with platinum-based chemotherapy	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase; DNA (platinum agents)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifolate antimetabolite combined with platinum-based chemotherapy class)

Avistone Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pemetrexed plus Carboplatin or Cisplatin — Competitive Intelligence Brief. https://druglandscape.com/ci/pemetrexed-plus-carboplatin-or-cisplatin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab